Dr. Max Lataillade is Vice President and Head of Global Research Strategy at ViiV Healthcare. Max’s career has spanned both industry and clinical practice in academia and the community. He has held numerous positions of increasing leadership and responsibility within several research and development organizations. He also brings his clinic experience and a patient-centered approach to his work. Max is credited for championing the development of Rukobia (Fostemsavir: HIV-1 Attachment Inhibitor), rapidly introducing and implementing early development structure and processes, and early development teams within ViiV to efficiently develop novel antiretroviral agents from discovery to the clinic.
In his role as Vice President and Head of Global Research Strategy at ViiV Healthcare, Max is responsible for global research and development strategy for the HIV pipeline. He oversees end-toend research and development activities for fostemsavir, and all novel HIV pipeline programs designed to address key unmet medical needs for people living with HIV (PLWHIV). Max ultimately is accountable for several dedicated and diverse teams and leads several programs with a focused approach on developing new antiretroviral agents that are safe and well tolerated, with novel mechanisms of action for the treatment, prevention, and ultimately cure of HIV. Max continues to practice as a physician with a very diversified practice. He is an Assistant Professor and teaches attending physicians at Yale School of Medicine in New Haven, Connecticut, and volunteers at the West Haven VA HIV clinic in Connecticut.
Prior to joining ViiV, Max was Vice President and Head of Global Development for HIV at Bristol-Myers Squibb (BMS) where he joined the global clinical research group in 2007 as an infectious disease physician and HIV specialist from Yale University School of Medicine. During his time at BMS, he played a central role in several virology programs in both HIV and HCV, helping to launch several medicines (including Reyataz and Sustiva for HIV-adults and pediatrics, Daklinza and Sunvepra for HCV). Max’s expertise in HIV and HIV/HCV co-infection, his vision and drive, and his leadership qualities have been recognized throughout the virology field, academia, and in the pharmaceutical industry. In 2014, he received the prestigious James Palmer Award for excellence in drug development (BMS R&D award), especially for his leadership and his team’s accelerated development of HIV-1 maturation inhibitors, and the attachment inhibitor fostemsavir. Max’s passion for developing new and innovative options for HIV patients is well known within and outside of ViiV.
Max obtained his medical degree from the University of Medicine and Dentistry New Jersey, completed his medical residency training at Temple University and Crozer-Chester Medical Center in Philadelphia in 2004, and finished his fellowship in Infectious Diseases and HIV at Yale University School of Medicine in 2007. Max’s sub-specialty training at Yale was in HIV resistance with a special focus on sequencing of antiretroviral agents for HIV positive patients who had developed HIV resistance and were in need of new antiretroviral agents.
Outside of work, Max continues to focus on HIV issues affecting minorities, especially African American women, as a member and consultant for the AIDS Minority Council. Max also focuses on helping with several health issues in Haiti since the 2011 earthquake. He is an avid sports fan and is very involved in his children’s scholastic and sporting activities. Max continues to play soccer every week as a member of the Guilford, Connecticut soccer club and is a devoted family man who enjoys going out, traveling, and exploring the world with his wife and family.